Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

Restrict the search for m clopidogrel to a specific field?

Approximate Matches

2406
Any Name

2392
Standardized Name

1225
Reference Text / Citation

522
Display Name

362
Note

205
Reference URL

175
Related Substance Name

76
Organism Author

68
Relationship Comments

48
Mixture Component Name

34
Code Literal

30
root_modifications_structuralModifications_molecularFragment_refPname

22
Code Comments

17
WIKIPEDIA

17
root_modifications_structuralModifications_residueModified

17
Protein Structural Modification Residue

16
Code URL

9
Structure Stereo Comments

8
ALANWOOD

6
EMA ASSESSMENT REPORTS

Showing 3861 - 3870 of 4747 results

First page
Previous page
Next page
Next page

MYCOBACTERIUM BOVIS BCG

D3GOY6203T

Status:

Possibly Marketed Outside US

Source:

UK NHS:Mycobacterium bovis BCG

Source URL:

https://tripod.nih.gov/npc/#Download

Class:

STRUCTURALLY DIVERSE

THERIDION CURASSAVICUM

9Z8D3HEM8L

Status:

Possibly Marketed Outside US

Source:

Canada:THERIDION

Source URL:

https://tripod.nih.gov/npc/#Download

Class:

STRUCTURALLY DIVERSE

URTICA URENS WHOLE

IHN2NQ5OF9

Status:

Possibly Marketed Outside US

Source:

Canada:URTICA URENS

Source URL:

https://tripod.nih.gov/npc/#Download

Class:

STRUCTURALLY DIVERSE

Silicified Microcrystalline Cellulose (65 µm)

K2EZE348C4

Status:

Excipient

Source:

Source URL:

https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm?event=browseByLetter.page&Letter=S

Class:

G1 SPECIFIED SUBSTANCE

Tosylamide/Formaldehyde Resin (80% n-Butyl acetate dispersion)

7D4DLW89CB

Status:

Other

Class:

G1 SPECIFIED SUBSTANCE

HLA class I COVID-19 peptide targets

D9QD5G5TPX

Status:

Other

Class:

G1 SPECIFIED SUBSTANCE

Rebaudioside M 85%

X3YJ76S94Z

Status:

Other

Class:

G1 SPECIFIED SUBSTANCE

MATRIX-M1 ADJUVANT

YZ7P8Y8ECX

Status:

Other

Class:

G1 SPECIFIED SUBSTANCE

AS04

C8385V1KQ6

Status:

Other

Class:

G1 SPECIFIED SUBSTANCE

LUCINACTANT

5BSH2G9BH8

Status:

US Previously Marketed

Source:

SURFAXIN by LEES PHARM HK

(2012)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021746

First approved in 2012

Source:

SURFAXIN by LEES PHARM HK

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021746

Class:

G1 SPECIFIED SUBSTANCE

Structurally Diverse

MYCOBACTERIUM BOVIS BCG

Structurally Diverse

THERIDION CURASSAVICUM

Structurally Diverse

URTICA URENS WHOLE

Concept

Silicified Microcrystalline Cellulose (65 µm)

7D4DLW89CB
Not a public record

Concept

Tosylamide/Formaldehyde Resin (80% n-Butyl acetate dispersion)

D9QD5G5TPX
Not a public record

Concept

HLA class I COVID-19 peptide targets

X3YJ76S94Z
Not a public record

Concept

Rebaudioside M 85%

YZ7P8Y8ECX
Not a public record

Concept

MATRIX-M1 ADJUVANT

Concept

AS04

Concept

LUCINACTANT

Showing 3861 - 3870 of 4747 results

First page
Previous page
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1